Abstract
The purpose of this study is to determine the dosage for oral and IM Cabotegravir LA and IM
Rilpiverine LA and evaluate the safety, acceptability, tolerability, and pharmacokinetics of
oral and long-acting injectable cabotegravir and long-acting injectable rilpivirine in
virologically suppressed HIV-infected children and adolescents.
